Last checked at 19 Oct 2015 07:00
19 October 2015
Evocutis plc
("Evocutis" or the "Company")
Admission of ordinary shares to the ISDX Growth Market
The Company announces that, with effect from 8:00 a.m. today, the Company's ordinary shares will commence trading on the ISDX Growth Market under the ticker EVO.
The Company's ordinary shares continue to be traded on AIM.
For further information please visit www.evocutis.com or contact the following:
David Lenigas / Donald Strang | Evocutis plc | +44 (0) 20 7440 0640
|
James Caithie / Liam Murray
| Cairn Financial Advisers LLP | +44 (0) 20 7148 7900 |
Company Information
Evocutis is an investment company which is admitted to trading on AIM, focussed on the investment in, or acquisition of, companies or projects in the natural resources sector.
The Company has a 10% interest in Brazil Tungsten Holdings Limited ("BTHL") which owns a 25 year lease over (with the option to extend) the producing Bodó Tungsten Mine ("Bodó") in Rio Grande do Norte, Brazil, by investing US$1 million in new capital in BTHL for the specific purposes of mine expansion.
It also has a 2% interest in Horse Hill Developments Ltd ("HHDL"), the 65% owners and operators of UK onshore exploration licences PEDL 137 and PEDL 246 (known as "Horse Hill").
Directors
The full names of the Directors of the Company and positions are as follows:
David Anthony Lenigas, Executive Chairman
Mr. Lenigas holds a Bachelor of Applied Science Degree in Mining Engineering. He served as Executive Chairman of London listed Lonrho Plc from 2006 to September 2012 and was in charge of Lonrho Plc's expansion into over 20 countries in Africa with its main focus on agri-logistics. He has extensive experience operating in the public company environment across the UK, African, Canadian and Australian markets. He also serves as an Executive Chairman of a number of other publicly listed companies.
Donald Ian George Layman Strang, Finance Director
Mr. Strang is a member of the Australian Institute of Chartered Accountants and has been in business over 20 years, holding senior financial and management positions in both publicly listed and private enterprises in Australia, Europe and Africa. Mr. Strang has considerable corporate and international expertise and over the past decade has focussed on mining and exploration activities. Mr Strang is a member of both the Audit and Remuneration committees.
Hamish Hamlyn Harris, Non-Executive Director
Mr. Harris holds a Bachelor of Commerce degree and has worked in the investment banking industry for over 15 years in Singapore, Hong Kong and London, primarily in the area of market risk management. He has also run a privately owned private equity vehicle targeting acquisitions in agriculture in Eastern Europe in the last few years and is currently a director of Polemos plc and Doriemus plc.
Sector Classification
Evocutis will be classified as a financial services company on ISDX.
Significant Shareholdings
Shareholder | Number of Ordinary Shares held | Percentage of Issued Share Capital |
HSBC Global Custody Nominee (UK) | 67,500,000 | 9.31% |
Fitel Nominees Limited | 63,916,667 | 8.82% |
Green Hair Services Limited | 62,250,000 | 8.59% |
Academy Minerals LTD | 60,000,000 | 8.28% |
Nomura PB Nominees Limited | 32,500,000 | 4.48% |
TD Direct Investing Nominees | 23,710,108 | 3.27% |
FERLIM Nominees Limited | 22,666,667 | 3.13% |
David Lenigas, Donald Strang and Hamish Harris each hold options over 10,000,000 ordinary shares in the Company at an exercise price of 0.22p; they do not hold any ordinary shares.
The percentage of securities in public hands is 65%. There are no restrictions on the transfer of Evocutis' securities.
Further Information
Evocutis was admitted to trading on AIM on 23 March 2006 as Syntopix Group plc ("Syntopix"); a copy of the admission document dated 17 March 2006 is available on the Company's website, www.evocutis.com. The Company subsequently changed its name on 25 October 2011, and on 19 March 2014 disposed of its trading operations and became an investing company. Prior to the disposal, Evocutis operated within the healthcare sector with a focus on advanced laboratory and clinical evaluations of skincare products for the health and cosmetic markets.
The Company will remain admitted to trading on AIM following admission to ISDX. Its ordinary shares are eligible for CREST settlement.
The Company is subject to the UK City Code on Takeovers and Mergers.
David Lenigas, Executive Chairman, commented: "We are seeking admission to ISDX as a means of further increasing liquidity and trading options for our shareholders and creating an additional platform on which to promote the Company's growth".
The directors of Evocutis Plc accept responsibility for this announcement.
COMPANY CONTACT DETAILS:
Evocutis plc
38 Jermyn Street
London
SW1Y 6DN
Telephone +44 (0)20 7440 0640
www.evocutis.com
CORPORATE ADVISER AND CONTACT DETAILS:
James Caithie / Liam Murray / Richard Nash
Cairn Financial Advisers LLP
61 Cheapside
London
EC2V 6AX
Telephone: +44 (0)20 7148 7900